NorthWest Biotherapeutics Inc (NWBO)

[GoodGuyBill]

NWBO 8K FILING

https://www.sec.gov/Archives/edgar/data/1072379/000110465919072581/tm1925173-1_8k.htm

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


Senior Management Team Appointment

On December 12, 2019, Northwest Biotherapeutics, Inc. (the “Company”) announced that it appointed Ms. Jean M. Davis, 48, as Chief Financial Officer, Chief Accounting Officer and Interim Chief Information Officer of the Company, effective December 9, 2019.

Ms. Davis is a Certified Public Accountant, Certified Sarbanes-Oxley Expert, Certified Internal Auditor and Certified Project Management Professional. Ms. Davis brings to the Company over 24 years of experience assisting both national and multi-national, public and private companies with their finance and accounting functions, financial reporting, compliance with financial, industry-specific and federal regulations and related matters. Ms. Davis obtained her Master of Science in Business with a concentration in Finance and Accounting from Johns Hopkins University.

Prior to joining the Company, Ms. Davis served as a Risk Advisory Senior Manager of BDO USA LLP, focused on assisting public national and multi-national companies to comply with Sarbanes-Oxley requirements and the remediation of identified internal control deficiencies. While at BDO in 2019, Ms. Davis assisted the Company with its SOX Section 404 evaluation of internal controls. From 2001 to 2018, Ms. Davis performed as an Audit Senior Manager and Project Manager at Cotton & Company LLP. Prior to Cotton & Company, Ms. Davis served as the Risk Management and Internal Audit Director at a public telecommunications company. Ms. Davis also worked previously at Deloitte & Touche LLP.

Ms. Davis will earn a salary of $265,000 per year, payable in accordance with the Company's standard payroll practices. The compensation package also includes 1,750,000 stock options that will vest on a pro-rata monthly basis over the first 36 months of employment, and 1,750,000 stock options that will vest based on milestones mutually agreed by the Company and Ms. Davis.

Except for her work for the Company while at BDO, Ms. Davis has no relationship with the Company, no family relationships with any of the Company’s directors or executive officers, and there have been no related party transactions between the Company and Ms. Davis reportable under Item 404(a) of Regulation S-K.